NewsBenzinga바이오헤이븐, ENA 2026 구두 총회 세션에서 발표한 1상 데이터에서 FGFR3 변이 요로상피암 및 두경부 편평세포암 환자에서 깊고 지속적인 반응 확인 바이오헤이븐, ENA 2026 구두 총회 세션에서 발표한 1상 데이터에서 FGFR3 변이 요로상피암 및 두경부 편평세포암 환자에서 깊고 지속적인 반응 확인 Benzinga 2026.11.19 12:37 (GMT+0) Open on Benzinga Other news Biohaven's Phase 1 Data Presented In Oral Plenary Session At ENA 2026 Shows Deep, Durable Responses In Patients With FGFR3-Altered Urothelial Cancer And Head And Neck Squamous Cell Carcinoma Clearmind Medicine Publishes Hong Kong Patent Application Covering Innovative Psychedelic Compounds Targeting Treatment Of PTSD And Other Mental Health Disorders Warner Music Gr Q4 Adj. EPS $0.55 Beats $0.36 Estimate, Sales $2.001B Beat $1.906B Estimate Biohaven Presents Clinical Data From Ongoing Phase 1 Study Of BHV-1530, Potential FGFR3-Directed ADC With Topoisomerase I Payload, At ENA 2026 Bernstein Maintains Outperform on Agilon Health, Raises Price Target to $138 Palo Alto Networks Stock Soars: Investors Cheer Strong Outlook, Applied Compute Acquisition
Biohaven's Phase 1 Data Presented In Oral Plenary Session At ENA 2026 Shows Deep, Durable Responses In Patients With FGFR3-Altered Urothelial Cancer And Head And Neck Squamous Cell Carcinoma
Clearmind Medicine Publishes Hong Kong Patent Application Covering Innovative Psychedelic Compounds Targeting Treatment Of PTSD And Other Mental Health Disorders
Biohaven Presents Clinical Data From Ongoing Phase 1 Study Of BHV-1530, Potential FGFR3-Directed ADC With Topoisomerase I Payload, At ENA 2026